All VCS sites will be conducting temperature checks for all patients and visitors at entrances. For your safety, you will be asked to use a mask, if you do not have one, a mask will be provided. If a person presents with a temperature, you will be asked to return home and further instructions will be given by your health care team. For our patients protection, no visitors under 18 will be allowed in the offices, there is a limit one (1) visitor per patient if necessary. No visitors are allowed in the chemo infusion room. Telemedicine visits are now available for routine office visits. VCS is keeping updated on current state and local guidance for the Covid vaccine rollout plan – until then please be advised our office will not write letters of recommendation or advise patients until the state and federal guidelines are published. FOR THE LATEST UP TO DATE INFORMATION, ALERTS, VACCINE INFORMATION AND CANCELLATIONS PLEASE CLICK HERE

Clinical Trial: 19064

Trial Status: Open
Trial Type: Multiple Myeloma
Disease Type: Multiple Myeloma
Trial ID 19064
Sponsor ID

A PHASE Ia/Ib OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND PHARMACOKINETICS OF TIRAGOLUMAB AS A SINGLE AGENT AND IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA, AND AS A SINGLE AGENT AND IN COMBINATION WITH RITUXIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA.(GO41036)

Principal Investigator
Gregory J. Orloff, MD

Locations

Fairfax Office

Learn More About This Trial
Other Relevant Trials
Trial ID 19247
Sponsor ID Janssen

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant (54767414MMY3021)

Principal Investigator
Mitul Gandhi, MD
5 Locations
Trial ID 19021
Sponsor ID Incye/IQVIA

A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma (INCB 01158-206)

Principal Investigator
Dipti Patel-Donnelly, MD